Optimal Glycemic Targets Examined for Short-Term Intensive Insulin Tx

This article originally appeared here.
Findings among newly diagnosed diabetes patients undergoing short-term intensive insulin therapy
Findings among newly diagnosed diabetes patients undergoing short-term intensive insulin therapy

HealthDay News — Stricter glycemic control during short-term intensive insulin therapy for newly diagnosed type 2 diabetes patients is associated with a higher likelihood of remission at 1 year, according to a study published online November 30 in the Journal of Diabetes Investigation.

Liehua Liu, MD, PhD, from First Affiliated Hospital of Sun Yat-Sen University in China, and colleagues sought to determine optimal glycemic targets during short-term intensive insulin therapy in patients with newly diagnosed type 2 diabetes. Insulin pumps were used to achieve and maintain glycemic targets (fasting blood glucose <6.1 mmol/L; 2-hour post-prandial blood glucose <8 mmol/L) for 14 days. Daily 8-point capillary blood glucose profiles were recorded. 

Related Articles

The researchers found that mean blood glucose was independently associated with improving acute insulin response (P=0.015) and 1-year remission (odds ratio, 0.12) but negatively associated with more Level-1 hypoglycemia (P=0.001). Major hypoglycemia was rare. Patients in the middle and lower mean blood glucose tertiles had higher 1-year remission rates versus the upper tertile (68.7 and 75% versus 32.3%; both P<0.001). Compared with the upper tertile, only the middle tertile did not have increased hypoglycemia (P=0.48).

"Based on glycemic parameters in the middle mean tertile, we propose new glycemic targets that are about 0.4 mmol/L lower than current ones as long-term benefit outweighs short-term risks," the authors write.

Abstract
Full Text